BO1 Stock Overview A biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
BioCryst Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for BioCryst Pharmaceuticals Historical stock prices Current Share Price US$7.77 52 Week High US$7.83 52 Week Low US$3.84 Beta 1.76 1 Month Change 3.68% 3 Month Change 20.22% 1 Year Change 32.93% 3 Year Change -44.55% 5 Year Change 215.69% Change since IPO 70.23%
Recent News & Updates
BioCryst Pharmaceuticals, Inc. Launches ORLADEYO® (berotralstat) in Ireland Nov 21
New minor risk - Share price stability Nov 17
BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026 Nov 05
Third quarter 2024 earnings released: US$0.068 loss per share (vs US$0.19 loss in 3Q 2023) Nov 05
BioCryst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 21
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting Orladeyo (Berotralstat) Oct 14 See more updates
BioCryst Pharmaceuticals, Inc. Launches ORLADEYO® (berotralstat) in Ireland Nov 21
New minor risk - Share price stability Nov 17
BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026 Nov 05
Third quarter 2024 earnings released: US$0.068 loss per share (vs US$0.19 loss in 3Q 2023) Nov 05
BioCryst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 21
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting Orladeyo (Berotralstat) Oct 14
BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome Oct 02
Insufficient new directors Oct 01
BioCryst Pharmaceuticals, Inc. Announces Successfully Completed Negotiations with the Pan-Canadian Pharmaceutical Alliance (Pcpa) for Oral, Once-Daily Prorladeyo® (Berotralstat) Sep 17
Biocryst Pharmaceuticals, Inc. Appoints Donald Fong as Chief Medical Officer Sep 05
Second quarter 2024 earnings released: US$0.061 loss per share (vs US$0.40 loss in 2Q 2023) Aug 06
BioCryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024 Aug 05
BioCryst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 05, 2024 Jul 22
New major risk - Share price stability May 31
Senior VP recently bought €187k worth of stock May 16
BioCryst Pharmaceuticals, Inc. Announces Federal Commission for Protection Against Health Risks in Mexico Grants Approval for Oral, Once-Daily ORLADEYO May 15
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO May 10 Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024 May 08
First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.28 loss in 1Q 2023) May 06
BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024 Apr 28
BioCryst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 06, 2024 Apr 23
BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency Apr 17
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024 Feb 29
Full year 2023 earnings released: US$1.18 loss per share (vs US$1.33 loss in FY 2022) Feb 26
BioCryst Launches Orladeyo (Berotralstat) in Italy Feb 20
BioCryst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 26, 2024 Feb 13
Forecast breakeven date pushed back to 2026 Jan 09
BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024 Jan 06
BioCryst Pharmaceuticals, Inc. Announces Publication of Data from Open-Label Extension of the APeX-2 Pivotal Trial of ORLADEYO(R) (berotralstat) Dec 19
New major risk - Share price stability Dec 08
Biocryst Pharmaceuticals, Inc. Announces Retirement of Kenneth B. Lee from the Board of Directors, Effective December 31, 2023 Dec 01
Biocryst Announces Approval of Orladeyo®? (Berotralstat) by the National Administration of Drugs, Foods, and Medical Devices in Argentina Nov 29
BioCryst Pharmaceuticals, Inc. Announces Spanish Ministry for Health Grants Marketing Authorization for Oral, Once-Daily ORLADEYO Nov 22
BioCryst Pharmaceuticals, Inc. Presents New Real-World Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-Inhibitor Following Long-Term Treatment with ORLADEYO(R) (berotralstat) Nov 11
New minor risk - Shareholder dilution Nov 10
No longer forecast to breakeven Nov 04
BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for Full Year 2023 Nov 03
No longer forecast to breakeven Nov 03
BioCryst Pharmaceuticals, Inc. to Present New ORLADEYO®? (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology Oct 28
Biocryst Pharmaceuticals, Inc. Begins Enrollment in Proof-Of-Concept Trial to Confirm Safe, Effective, Once-Daily Dose of Oral Factor D Inhibitor, Bcx10013 Oct 27
BioCryst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 20
INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec Sep 19
Second quarter 2023 earnings released: US$0.40 loss per share (vs US$0.32 loss in 2Q 2022) Aug 04
BioCryst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 23
Biocryst Pharmaceuticals, Inc. Announces Executive Changes Jul 12
BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Public Health Institute of Chile May 23
First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.40 loss in 1Q 2022) May 03
Full year 2022 earnings released: US$1.33 loss per share (vs US$1.03 loss in FY 2021) Feb 22
BioCryst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 21, 2023 Feb 08
BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating Orladeyo(R) (Berotralstat) in Pediatric Patients with Hereditary Angioedema Jan 27
BioCryst Pharmaceuticals, Inc. Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases Jan 10
Forecast to breakeven in 2025 Dec 31
BioCryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) by the Israeli Ministry of Health Nov 29
High number of new directors Nov 16
Biocryst Presents Real-World Data Showing Rapid and Sustained Hae Attack Rate Reduction After Beginning Orladeyo® (Berotralstat), Regardless of Prior Prophylactic Therapy Nov 11
Third quarter 2022 earnings released: US$0.23 loss per share (vs US$0.33 loss in 3Q 2021) Nov 02
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022 Nov 02
BioCryst Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022 Oct 19
BioCryst Pharmaceuticals, Inc. Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold as Chief Medical Officer Sep 15
FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva Sep 01
Biocryst Presents Data Demonstrating >99% Suppression of Alternative Pathway Complement Activity with Bcx9930 in C3g Patients Aug 27
Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) in Saudi Arabia Aug 19
BioCryst Pharmaceuticals, Inc. Resumes Enrollment in BCX9930 Clinical Program Aug 06
Second quarter 2022 earnings released: US$0.32 loss per share (vs US$0.24 loss in 2Q 2021) Aug 05
Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022 Aug 05
BioCryst Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 22
BioCryst Pharmaceuticals, Inc. Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat) Jul 02
BioCryst Announces ORLADEYO(R) (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022 Jun 23
Biocryst Pharmaceuticals, Inc. Announces FDA Grants Fast Track Designation for ALK-2 Inhibitor, BCX9250 Jun 10
Biocryst Pharmaceuticals, Inc. Announces FDA Grants Fast Track Designation for ALK-2 Inhibitor, BCX9250 Jun 09
Biocryst Pharmaceuticals, Inc. Announces Approval of Orladeyo(R) (Berotralstat) by Swissmedic Jun 08
Biocryst Announces Health Canada Has Authorized Orladeyo® (Berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks Jun 07
First quarter 2022 earnings released: US$0.40 loss per share (vs US$0.36 loss in 1Q 2021) May 06
BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2022 May 06
European Medicines Agency Grants PRIME Designation to BioCryst Pharmaceuticals, Inc.'s ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans Progressiva Apr 28
High number of new directors Apr 27
BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2022 Apr 26
BioCryst Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 22
BioCryst Pharmaceuticals, Inc. Pauses Enrollment in BCX9930 Clinical Trials Apr 09
High number of new directors Apr 01
High number of new directors Mar 02
Biocryst Pharmaceuticals, Inc. Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among Hae Patients Following Long-Term Treatment with Orladeyo Feb 25
No longer forecast to breakeven Feb 25
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 24 BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022
BioCryst Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 10
BioCryst Appoints Machelle Sanders to Board of Directors Feb 09
BioCryst Pharmaceuticals, Inc. Provides ORLADEYO Net Revenue and Peak Sales Guidance for Full Year 2022 Jan 12
BioCryst Pharmaceuticals, Inc. Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH Jan 09
Forecast to breakeven in 2024 Jan 01
BioCryst Pharmaceuticals, Inc Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH Dec 01
Director recently bought €82k worth of stock Nov 25
Third quarter 2021 earnings released: US$0.33 loss per share (vs US$0.26 loss in 3Q 2020) Nov 04
High number of new directors Sep 14
High number of new directors Sep 04
High number of new directors Sep 02
BioCryst Pharmaceuticals, Inc. Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Canada and Swissmedic Aug 26 Shareholder Returns BO1 DE Biotechs DE Market 7D 2.6% 6.5% 1.3% 1Y 32.9% -1.9% 9.0%
See full shareholder returns
Return vs Market: BO1 exceeded the German Market which returned 10.1% over the past year.
Price Volatility Is BO1's price volatile compared to industry and market? BO1 volatility BO1 Average Weekly Movement 7.6% Biotechs Industry Average Movement 7.3% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: BO1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: BO1's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases.
Show more BioCryst Pharmaceuticals, Inc. Fundamentals Summary How do BioCryst Pharmaceuticals's earnings and revenue compare to its market cap? BO1 fundamental statistics Market cap €1.63b Earnings (TTM ) -€120.86m Revenue (TTM ) €402.72m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BO1 income statement (TTM ) Revenue US$412.58m Cost of Revenue US$197.47m Gross Profit US$215.11m Other Expenses US$338.93m Earnings -US$123.82m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.60 Gross Margin 52.14% Net Profit Margin -30.01% Debt/Equity Ratio -176.9%
How did BO1 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/10 03:10 End of Day Share Price 2025/01/10 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources BioCryst Pharmaceuticals, Inc. is covered by 30 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Huidong Wang Barclays Tazeen Ahmad BofA Global Research Dae Gon Ha BTIG
Show 27 more analysts 
